Management of thrombotic thrombocytopenic purpura

被引:19
作者
Coppo, P. [1 ,2 ,3 ,4 ]
机构
[1] Univ Paris 06, Hop St Antoine, AP HP, Serv Hematol,Ctr Reference Microangiopathies Thro, 184,Rue Faubourg St Antoine, F-75012 Paris, France
[2] Hop St Antoine, Serv Hematol, 184,Rue Faubourg St Antoine, F-75012 Paris, France
[3] Inst Gustave Roussy, Inserm U1170, Villejuif, France
[4] Univ Paris 06, Univ Sorbonne Paris Pierree & Marie Curie, Paris, France
关键词
Thrombotic thrombocytopenic purpura; ADAMTS13; Plasma exchange; Rituximab; Immunotherapy; MICROANGIOPATHIES REFERENCE CENTER; THERAPEUTIC PLASMA-EXCHANGE; SUBOPTIMAL RESPONSE; RITUXIMAB; EFFICACY; EXPERIENCE; SAFETY; MULTICENTER; TTP;
D O I
10.1016/j.tracli.2017.05.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Daily therapeutic plasma exchange (TPE) transformed the historically fatal prognosis of acquired, anti-ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura (TTP), leading to the current overall survival rates of >80%. However, relapses occur in up to 40% of patients and refractory disease with fatal outcomes still occurs, typically within the first days of management. In this context, the introduction of rituximab has been the second major breakthrough in TTP management. Rituximab is now routinely recommended during the acute phase, typically in patients with a suboptimal response to treatment, and increasingly as frontline therapy, with high response rates in the following weeks. In more severe patients, salvage strategies typically include twice daily TPE, pulses of cyclophosphamide, as well as splenectomy in the more desperate cases. In this life-threatening and debilitating disease, relapses can be efficiently prevented in patients with a severe acquired ADAMTS13 deficiency and otherwise in remission with the use of rituximab. In the coming years, the TTP therapeutic landscape should be enriched by original strategies stemming from clinical experience and new agents that are currently being evaluated in large, international, clinical trials. Promising agents under evaluation include caplacizumab (an inhibitor of the glycoprotein-Ib/IX-Von-Willebrand factor axis), N-acetylcysteine, recombinant ADAMTS13, and anti-plasmocyte compounds. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 21 条
[1]   Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study [J].
Benhamou, Ygal ;
Paintaud, Gilles ;
Azoulay, Elie ;
Poullin, Pascale ;
Galicier, Lionel ;
Desvignes, Celine ;
Baudel, Jean-Luc ;
Peltier, Julie ;
Mira, Jean-Paul ;
Pene, Frederic ;
Presne, Claire ;
Saheb, Samir ;
Deligny, Christophe ;
Rousseau, Alexandra ;
Feger, Frederic ;
Veyradier, Agnes ;
Coppo, Paul .
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) :1246-1251
[2]  
Cataland S, 2016, AM SOC HEM C
[3]   Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange [J].
Coppo, Paul ;
Froissart, Antoine .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, :637-643
[4]   Adjuvant rituximab to prevent TTP relapse [J].
Cuker, Adam .
BLOOD, 2016, 127 (24) :2952-2953
[5]   Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study [J].
de la Rubia, Javier ;
Moscardo, Federico ;
Gomez, Maria J. ;
Guardia, Ramon ;
Rodriguez, Pilar ;
Sebrango, Ana ;
Zamora, Concepcion ;
Deben, Guillermo ;
Goterris, Rosa ;
Lopez, Rafaela ;
Pena, Francisco ;
Pujol, Misericordia ;
Vidaller, Antonio ;
del Rio-Garma, Julio ;
Sanz, Miguel A. .
TRANSFUSION AND APHERESIS SCIENCE, 2010, 43 (03) :299-303
[6]   Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura [J].
Falter, Tanja ;
Schmitt, Veronique ;
Herold, Stephanie ;
Weyer, Veronika ;
von Auer, Charis ;
Wagner, Stefanie ;
Hefner, Gudrun ;
Beutel, Manfred ;
Lackner, Karl ;
Laemmle, Bernhard ;
Scharrer, Inge .
TRANSFUSION, 2017, 57 (05) :1152-1162
[7]   Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis [J].
Fleury, I. ;
Chevret, S. ;
Pfreundschuh, M. ;
Salles, G. ;
Coiffier, B. ;
van Oers, M. H. J. ;
Gisselbrecht, C. ;
Zucca, E. ;
Herold, M. ;
Ghielmini, M. ;
Thieblemont, C. .
ANNALS OF ONCOLOGY, 2016, 27 (03) :390-397
[8]   Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center [J].
Froissart, Antoine ;
Buffet, Marc ;
Veyradier, Agnes ;
Poullin, Pascale ;
Provot, Francois ;
Malot, Sandrine ;
Schwarzinger, Michael ;
Galicier, Lionel ;
Vanhille, Philippe ;
Vernant, Jean-Paul ;
Bordessoule, Dominique ;
Guidet, Bertrand ;
Azoulay, Elie ;
Mariotte, Eric ;
Rondeau, Eric ;
Mira, Jean-Paul ;
Wynckel, Alain ;
Clabault, Karine ;
Choukroun, Gabriel ;
Presne, Claire ;
Pourrat, Jacques ;
Hamidou, Mohamed ;
Coppo, Paul .
CRITICAL CARE MEDICINE, 2012, 40 (01) :104-111
[9]   Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre [J].
Grall, Maximilien ;
Azoulay, Elie ;
Galicier, Lionel ;
Provot, Francois ;
Wynckel, Alain ;
Poullin, Pascale ;
Grange, Steven ;
Halimi, Jean-Michel ;
Lautrette, Alexandre ;
Delmas, Yahsou ;
Presne, Claire ;
Hamidou, Mohamed ;
Girault, Stephane ;
Pene, Frederic ;
Perez, Pierre ;
Kanouni, Tarik ;
Seguin, Amelie ;
Mousson, Christiane ;
Chauveau, Dominique ;
Ojeda-Uribe, Mario ;
Barbay, Virginie ;
Veyradier, Agnes ;
Coppo, Paul ;
Benhamou, Ygal .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) :381-387
[10]   Thrombotic thrombocytopenic purpura [J].
Hovinga, Johanna A. Kremer ;
Coppo, Paul ;
Laemmle, Bernhard ;
Moake, Joel L. ;
Miyata, Toshiyuki ;
Vanhoorelbeke, Karen .
NATURE REVIEWS DISEASE PRIMERS, 2017, 3